glp 1 receptor agonist contraindications to The cardiovascular effects of GLP-1 agonists beyond obesity and contraindications to glp 1 Dr
Description
The Glp1r / C57BL/6J ( Glp1r KO) mice generated and provided by Dr
In the SUSTAIN-6 study, which compared subcutaneous semaglutide to placebo, DR complications occurred in 3% of semaglutide and 1.8% of placebo subjects
All of the dynamics around GLP-1s, compounding shortage workarounds, and potential for DTC telehealth fallout I described last August seem to be playing out in 2025
Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial (FIGHT) JAMA
DAlessio DA
Thats a question preventive cardiologists can find frustrating, for at least two reasons
